Alivus Life Sciences Limited Share Price & Analysis
₹1,145.4▲ +1.16%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹1,145.4
+1.16%
Open
₹—
High
₹1,159.1
Low
₹1,130
Close
₹1,145.4
52W High
₹1,194
52W Low
₹819
Volume
42K
Lot Size
1
Sector
Healthcare
Market Cap
₹14K Cr
Face Value
₹2
Mid Cap
Price Chart
Fundamentals
P/E
39.6
Sector P/E
54.4
P/B
3.87
EPS
₹45.9
ROE
18.36%
ROCE
—
D/E Ratio
0.02
Div Yield
0.44%
Book Value
₹271.02
+
Strengths
- ✓Strong return on equity (ROE 18.4%)
- ✓Attractively valued vs sector (P/E 39.6x vs industry 54.4x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ALIVUS · as of Mar 2026
Promoters74.99%▼0.01
FII6.57%▼0.17
DII5.19%▲0.33
Public13.25%▼0.15
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 82.85% | 82.85% | 82.85% | 75.00% | 75.00% | 74.99% |
| FII | 4.57% | 5.01% | 4.81% | 7.85% | 6.74% | 6.57% |
| DII | 0.74% | 1.41% | 1.57% | 4.16% | 4.86% | 5.19% |
| Public | 11.84% | 10.73% | 10.76% | 12.99% | 13.40% | 13.25% |
Corporate Events
Dividend - Rs 5 Per Share
Dividend31 Aug 2025
Interim Dividend - Rs 22.50 Per Share
Dividend16 Oct 2023
Annual General Meeting
AGM21 Sept 2023
About Alivus Life Sciences Limited
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Alivus Life Sciences Limited share price today?▾
Alivus Life Sciences Limited (ALIVUS) is currently trading at ₹1,145.4 on NSE, up 1.16% as of the last market session. Prices update daily after market close on MarketNetra.
Is Alivus Life Sciences Limited available in F&O (Futures & Options)?▾
Yes, Alivus Life Sciences Limited (ALIVUS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Alivus Life Sciences Limited 52-week high and low?▾
Alivus Life Sciences Limited's 52-week high is ₹1,194 and the 52-week low is ₹819. The current price of ₹1,145.4 is 4.1% below the 52W high.
What is Alivus Life Sciences Limited P/E ratio?▾
Alivus Life Sciences Limited's current P/E ratio is 39.6. This indicates the market is paying ₹39.6 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Alivus Life Sciences Limited options?▾
Alivus Life Sciences Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade ALIVUS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.